After more than ten years treading a solid academic trajectory in the interface between psychology, neuroscience and psychiatry, I started developing initiatives to provide new psychiatric treatments. During my undergrad, Masters and PhD studies and post-doctoral research, I specialized in psychoactive substances, studying their most varied effects - harmful as well as therapeutic - focusing on psychedelics (ayahuasca, LSD, ibogaine, MDMA and psilocybin, among others). I led and participated in groundbreaking research revealing the neural basis of psychedelic's effects in the human brain, helping to elucidate their effects in consciousness and also their promising therapeutic potentials. I have professional experiences with the first, second and third sectors (government, business and non-profits). Creative and determined, I work to bring radical and disruptive innovations in psychiatry, developing safer and better treatments than currently available, focusing on severe cases of drug addiction, depression and trauma, among others.